Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

This Week at Tailwinds…Scratching My Head

Perhaps it's because I've not seen the barber during the pandemic, but the market has me left me scratching my head. Some recent stock...

Mustang Bio Announces Pricing of Public Offering of Common Stock

Tailwinds' Take: I don't believe that Mustang could have had much better timing in getting this deal done. Fortress Bio (FBIO) is the largest...

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

Tailwinds' Take: these results are not at all unexpected, but they add further confirmation to the thesis that Avenue's IV Tramadol will be approved...

June Preview…Plus Much More!

May was another strong month for the market as the stimulus package and expectations for a strong re-opening of the economy kept the rebound...

Moneyball for Biotech

Moneyball: The Art of Winning an Unfair Game is a book by Michael Lewis about the Oakland Athletics baseball team and its general manager Billy Beane. The focus of the...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

Tailwinds' Take: Fortress has a whole host of catalysts coming during 2020, as detailed in this shareholder update. Importantly, by breaking out the non-GAAP...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide...

Tailwinds' Take: this is another potential coup by Fortress, as their business model involves partnering on and developing novel therapies. Their ability to create...

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

Tailwinds' Take: FBIO owns ~30% of Avenue. This news, while not unexpected, further cements the case for IV Tramadol being a well-used medication post...

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107...

Tailwinds' Take: a positive step towards approval of this needed therapy. Fortress Bio (FBIO), the parent of Mustang, has many such catalysts going forward...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

This Week In MicroCap

It was certainly a great week for the market as a number of positive factors contributed to the continuation of what is a very...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

Building Our Case for Fortress (FBIO)

In this, our third article about Fortress Biotech (FBIO), we discuss the value of two in-house subsidiaries, Journey Medical and Caelum BioSciences. Both entities...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.